Gyre Therapeutics Valuation

Q: What is the Fair Price of GYRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

GYRE ($11.93) is trading above our estimate of [[fair value]] ($7.9)

Is GYRE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GYRE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GYRE ($11.93) is trading above our estimate of fair value ($7.9)

Significantly Below Fair Value: GYRE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GYRE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for GYRE. This is calculated by dividing GYRE's market cap by their current preferred multiple.
What is GYRE's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$1.02b

GYRE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.8x
Enterprise Value/EBITDA	46.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does GYRE's PS Ratio compare to its peers?

The above table shows the PS ratio for GYRE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	17.2x
MDXG MiMedx Group	3.1x	10.7%	US$1.0b
IRWD Ironwood Pharmaceuticals	2.5x	13.0%	US$1.0b
ARQT Arcutis Biotherapeutics	10.1x	36.0%	US$1.1b
FDMT 4D Molecular Therapeutics	53.1x	54.1%	US$1.1b
GYRE Gyre Therapeutics	8.8x	n/a	US$1.0b

Price-To-Sales vs Peers: GYRE is good value based on its Price-To-Sales Ratio (8.8x) compared to the peer average (17.2x).

Price to Earnings Ratio vs Industry

How does GYRE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	24.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	24.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: GYRE is good value based on its Price-To-Sales Ratio (8.8x) compared to the US Biotechs industry average (11x).

Price to Sales Ratio vs Fair Ratio

What is GYRE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GYRE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	8.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GYRE's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.